Azithromycin: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz mNo edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[medicine]], '''azithromycin''' is a "semi-synthetic macrolide [[antibiotic]] structurally related to [[erythromycin]]. It has been used in the treatment of [[Mycobacterium avium | In [[medicine]], '''azithromycin''' is a "semi-synthetic macrolide [[antibiotic]] structurally related to [[erythromycin]]. It has been used in the treatment of [[Mycobacterium avium intracellular infection]]s, [[toxoplasmosis]], and [[cryptosporidiosis]]."<ref>{{MeSH}}</ref> | ||
==Development== | ==Development== | ||
Revision as of 14:55, 14 February 2009
In medicine, azithromycin is a "semi-synthetic macrolide antibiotic structurally related to erythromycin. It has been used in the treatment of Mycobacterium avium intracellular infections, toxoplasmosis, and cryptosporidiosis."[1]
Development
Azithromycin was patented in 1982.[2] Zithromax was approved by the Food and Drug Administration for Pfizer in 1991.[3] Non-authorized generic drugs manufactured by Teva, Sandoz, and Abraxis were approved in the United States starting in 2005.[3]
References
- ↑ Anonymous (2024), Azithromycin (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ patent:4328334 - Google Patents. Retrieved on 2009-02-01.
- ↑ 3.0 3.1 Drugs@FDA. Food and Drug Administration. Retrieved on 2009-02-01. Cite error: Invalid
<ref>tag; name "urlDrugs@FDA" defined multiple times with different content